• Home
  • News Reports
  • Locally developed fatty liver medicines possibly launched earlier with acquisition of related intellectual property rights by German pharmaceutical companies

Locally developed fatty liver medicines possibly launched earlier with acquisition of related intellectual property rights by German pharmaceutical companies

13 January 2020 | ResearchGeneral News

A research team from Duke-NUS Medical School’s Cardiovascular & Metabolic Disorders Programme, SingHealth Duke-NUS Academic Medical Centre, National Heart Centre Singapore and the Singapore-based biotech company, Enleofen Bio had discovered the role of a specific protein – interleukin 11 (IL-11) – in fibrotic diseases of the liver, lung, kidney, eye, skin and heart.

  • Home
  • News Reports
  • Locally developed fatty liver medicines possibly launched earlier with acquisition of related intellectual property rights by German pharmaceutical companies